Anna Leitgeb Ph.D
Project Leader

Employed in 2005, Anna Leitgeb is one of the inventors of sevuparin and its use in treating VOC in sickle-cell disease and in malaria. Anna has more than 10 years of experience in drug development, from preclinical to clinical phase II programs in both biotech and the pharmaceutical industry. During her Ph.D studies she designed the prototype of sevuparin and identified its potential clinical use during malaria infections. She previously worked at Pharmacia & Upjohn and AstraZeneca. Anna has an M.Sc in Chemistry from Stockholm University and a Ph.D in Medicine from Karolinska Institutet.

Telephone: +46 (0)70 320 48 73